# Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

> **NCT00927069** · PHASE3 · COMPLETED · sponsor: **Innovaderm Research Inc.** · enrollment: 85 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Adalimumab every other week
- **DRUG:** Adalimumab Every Week

## Key facts

- **NCT ID:** NCT00927069
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-09
- **Final completion:** 2008-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2011-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927069, "Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00927069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*